The new management installed by Bidvest following its hostile takeover in 2014 "starts to reveal the positive impact and favourable direction that a cleansed Adcock Ingram is capable of delivering", the pharmaceutical group said in its interim results on Wednesday morning. Adcock Ingram raised its interim dividend 26% to 63c thanks to a 66% jump in aftertax profit to R286m. The group’s revenue grew 11% to R3bn for the six months to end-December. During the reporting period, Adcock Ingram sold its Indian sales and marketing business for R328m, which was booked as a R49m accounting loss. The former Tiger Brands subsidiary reduced its stake in Ghanaian pharmaceutical company Ayrton from 78% to 25%, selling 53% for R11m, contributing an accounting profit of R1.3m. This means the new management has "effectively dealt with all other inherited underperforming assets", the company said. Adcock Ingram’s most recent annual report listed Bidvest as its largest shareholder, with a 37.5% stake, ...

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as exclusive Financial Times articles, ProfileData financial data, and digital access to the Sunday Times and Times Select.

Already subscribed? Simply sign in below.

Questions or problems? Email or call 0860 52 52 00. Got a subscription voucher? Redeem it now